Skip to content
1887

Journal of General Virology header logo Journal of General Virology

Volume 88, Issue 4

Discriminating between cellular and misfolded prion protein by using affinity to 9-aminoacridine compounds No Access

Abstract

Quinacrine and related 9-aminoacridine compounds are effective in eliminating the alternatively folded prion protein, termed PrP, from scrapie-infected cultured cells. Clinical evaluations of quinacrine for the treatment of human prion diseases are progressing in the absence of a clear understanding of the molecular mechanism by which prion replication is blocked. Here, insight into the mode of action of 9-aminoacridine compounds was sought by using a chemical proteomics approach to target identification. Cellular macromolecules that bind 9-aminoacridine ligands were affinity-purified from tissue lysates by using a 9-aminoacridine-functionalized solid-phase matrix. Although the 9-aminoacridine matrix was conformationally selective for PrP, it was inefficient: approximately 5 % of PrP was bound under conditions that did not support binding of the cellular isoform, PrP. Our findings suggest that 9-aminoacridine compounds may reduce the PrP burden either by occluding epitopes necessary for templating on the surface of PrP or by altering the stability of PrP oligomers, where a one-to-one stoichiometry is not necessary.

  • Received:
  • Accepted:
  • Published Online:
SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82601-0
2007-04-01
2026-01-17

Metrics

Loading full text...

Full text loading...

References

  1. Barret A., Tagliavini F., Forloni G., Bate C., Salmona M., Colombo L., De Luigi A., Limido L., Suardi S. other authors 2003; Evaluation of quinacrine treatment for prion diseases. J Virol 77:8462–8469 [CrossRef]
     [Google Scholar]
  2. Burdine L., Kodadek T. 2004; Target identification in chemical genetics: the (often) missing link. Chem Biol 11:593–597 [CrossRef]
     [Google Scholar]
  3. Butler D. A., Scott M. R., Bockman J. M., Borchelt D. R., Taraboulos A., Hsiao K. K., Kingsbury D. T., Prusiner S. B. 1988; Scrapie-infected murine neuroblastoma cells produce protease-resistant prion proteins. J Virol 62:1558–1564
     [Google Scholar]
  4. Carlson G. A., Kingsbury D. T., Goodman P. A., Coleman S., Marshall S. T., DeArmond S., Westaway D., Prusiner S. B. 1986; Linkage of prion protein and scrapie incubation time genes. Cell 46:503–511 [CrossRef]
     [Google Scholar]
  5. Carlson G. A., Ebeling C., Yang S. L., Telling G., Torchia M., Groth D., Westaway D., DeArmond S. J., Prusiner S. B. 1994; Prion isolate specified allotypic interactions between the cellular and scrapie prion proteins in congenic and transgenic mice. Proc Natl Acad Sci U S A 91:5690–5694 [CrossRef]
     [Google Scholar]
  6. Castilla J., Saa P., Soto C. 2005; Detection of prions in blood. Nat Med 11:982–985
     [Google Scholar]
  7. Chandler R. L. 1961; Encephalopathy in mice produced by inoculation with scrapie brain material. Lancet i:1378–1379
     [Google Scholar]
  8. Collins S. J., Lewis V., Brazier M., Hill A. F., Fletcher A., Masters C. L. 2002; Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 52:503–506 [CrossRef]
     [Google Scholar]
  9. Deleault N. R., Lucassen R. W., Supattapone S. 2003; RNA molecules stimulate prion protein conversion. Nature 425:717–720 [CrossRef]
     [Google Scholar]
  10. Dise C. A., Burch J. W., Goodman D. B. 1982; Direct interaction of mepacrine with erythrocyte and platelet membrane phospholipid. J Biol Chem 257:4701–4704
     [Google Scholar]
  11. Doh-Ura K., Iwaki T., Caughey B. 2000; Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 74:4894–4897 [CrossRef]
     [Google Scholar]
  12. Doh-ura K., Ishikawa K., Murakami-Kubo I., Sasaki K., Mohri S., Race R., Iwaki T. 2004; Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 78:4999–5006 [CrossRef]
     [Google Scholar]
  13. Farquhar C. F., Dornan J., Moore R. C., Somerville R. A., Tunstall A. M., Hope J. 1996; Protease-resistant PrP deposition in brain and non-central nervous system tissues of a murine model of bovine spongiform encephalopathy. J Gen Virol 77:1941–1946 [CrossRef]
     [Google Scholar]
  14. Gaugain B., Markovits J., Le Pecq J. B., Roques B. P. 1981; Hydrogen bonding in deoxyribonucleic acid base recognition. I. Proton nuclear magnetic resonance studies of dinucleotide-acridine alkylamide complexes. Biochemistry 20:3035–3042 [CrossRef]
     [Google Scholar]
  15. Girault S., Grellier P., Berecibar A., Maes L., Mouray E., Lemiere P., Debreu M. A., Davioud-Charvet E., Sergheraert C. 2000; Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker. J Med Chem 43:2646–2654 [CrossRef]
     [Google Scholar]
  16. Klingenstein R., Lober S., Kujala P., Godsave S., Leliveld S. R., Gmeiner P., Peters P. J., Korth C. 2006; Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments. J Neurochem 98:748 [CrossRef]
     [Google Scholar]
  17. Korth C., May B. C., Cohen F. E., Prusiner S. B. 2001; Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 98:9836–9841 [CrossRef]
     [Google Scholar]
  18. Lee K. S., Linden R., Prado M. A., Brentani R. R., Martins V. R. 2003; Towards cellular receptors for prions. Rev Med Virol 13:399–408 [CrossRef]
     [Google Scholar]
  19. Lee I. S., Long J. R., Prusiner S. B., Safar J. G. 2005; Selective precipitation of prions by polyoxometalate complexes. J Am Chem Soc 127:13802–13803 [CrossRef]
     [Google Scholar]
  20. Le Pecq J. B., Le Bret M., Barbet J., Roques B. 1975; DNA polyintercalating drugs: DNA binding of diacridine derivatives. Proc Natl Acad Sci U S A 72:2915–2919 [CrossRef]
     [Google Scholar]
  21. Ma K., Sourkes T. L. 1980; Inhibition of diamine oxidase by antimalarial drugs. Agents Actions 10:395–398 [CrossRef]
     [Google Scholar]
  22. Madore N., Smith K. L., Graham C. H., Jen A., Brady K., Hall S., Morris R. 1999; Functionally different GPI proteins are organized in different domains on the neuronal surface. EMBO J 18:6917–6926 [CrossRef]
     [Google Scholar]
  23. Marsh R. F., Kimberlin R. H. 1975; Comparison of scrapie and transmissible mink encephalopathy in hamsters. II. Clinical signs, pathology, and pathogenesis. J Infect Dis 131:104–110 [CrossRef]
     [Google Scholar]
  24. May B. C., Fafarman A. T., Hong S. B., Rogers M., Deady L. W., Prusiner S. B., Cohen F. E. 2003; Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc Natl Acad Sci U S A 100:3416–3421 [CrossRef]
     [Google Scholar]
  25. May B. C., Witkop J., Sherrill J., Anderson M. O., Madrid P. B., Zorn J. A., Prusiner S. B., Cohen F. E., Guy R. K. 2006a; Structure-activity relationship study of 9-aminoacridine compounds in scrapie-infected neuroblastoma cells. Bioorg Med Chem Lett 16:4913–4916 [CrossRef]
     [Google Scholar]
  26. May B. C., Zorn J. A., Witkop J., Sherrill J., Wallace A. C., Legname G., Prusiner S. B., Cohen F. E. 2006b; Structure–activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J Med Chem 50:65–73
     [Google Scholar]
  27. Mustonen P., Lehtonen J. Y., Kinnunen P. K. 1998; Binding of quinacrine to acidic phospholipids and pancreatic phospholipase A2. Effects on the catalytic activity of the enzyme. Biochemistry 37:12051–12057 [CrossRef]
     [Google Scholar]
  28. Nazor K. E., Kuhn F., Seward T., Green M., Zwald D., Purro M., Schmid J., Biffiger K., Power A. M. other authors 2005; Immunodetection of disease-associated mutant PrP, which accelerates disease in GSS transgenic mice. EMBO J 24:2472–2480 [CrossRef]
     [Google Scholar]
  29. Oesch B., Westaway D., Walchli M., McKinley M. P., Kent S. B., Aebersold R., Barry R. A., Tempst P., Teplow D. B. other authors 1985; A cellular gene encodes scrapie PrP 27-30 protein. Cell 40:735–746 [CrossRef]
     [Google Scholar]
  30. Pajeva I. K., Wiese M., Cordes H. P., Seydel J. K. 1996; Membrane interactions of some catamphiphilic drugs and relation to their multidrug-resistance-reversing ability. J Cancer Res Clin Oncol 122:27–40 [CrossRef]
     [Google Scholar]
  31. Prusiner S. B. 2004 Prion Biology and Diseases , 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press;
     [Google Scholar]
  32. Ryou C., Legname G., Peretz D., Craig J. C., Baldwin M. A., Prusiner S. B. 2003; Differential inhibition of prion propagation by enantiomers of quinacrine. Lab Invest 83:837–843 [CrossRef]
     [Google Scholar]
  33. Ryou C., Lessard P., Freyman Y., Guglielmo B. J., Yung L., Baldwin M. A., Craig J. C., DeArmond S., May B. C. H. other authors 2004; In vivo efficacy of quinacrine in animal models of prion disease. In The First International Conference of the Network of Excellence NeuroPrion Paris p– 169 http://www.neuroprion.com/pdf_docs/conferences/prion2004/abstract_book.pdf
     [Google Scholar]
  34. Safar J. G., Kellings K., Serban A., Groth D., Cleaver J. E., Prusiner S. B., Riesner D. 2005a; Search for a prion-specific nucleic acid. J Virol 79:10796–10806 [CrossRef]
     [Google Scholar]
  35. Safar J. G., Geschwind M. D., Deering C., Didorenko S., Sattavat M., Sanchez H., Serban A., Vey M., Baron H. other authors 2005b; Diagnosis of human prion disease. Proc Natl Acad Sci U S A 102:3501–3506 [CrossRef]
     [Google Scholar]
  36. Sebestik J., Safarik M., Stibor I., Hlavacek J. 2006; Acridin-9-yl exchange: a proposal for the action of some 9-aminoacridine drugs. Biopolymers 84:605–614 [CrossRef]
     [Google Scholar]
  37. Spitzmaul G., Dilger J. P., Bouzat C. 2001; The noncompetitive inhibitor quinacrine modifies the desensitization kinetics of muscle acetylcholine receptors. Mol Pharmacol 60:235–243
     [Google Scholar]
  38. Stahl N., Borchelt D. R., Hsiao K., Prusiner S. B. 1987; Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 51:229–240 [CrossRef]
     [Google Scholar]
  39. Stuhlmeier K. M. 2003; Mepacrine inhibits matrix metalloproteinases-1 (MMP-1) and MMP-9 activation in human fibroblast-like synoviocytes. J Rheumatol 30:2330–2337
     [Google Scholar]
  40. Supattapone S., Bosque P., Muramoto T., Wille H., Aagaard C., Peretz D., Nguyen H. O., Heinrich C., Torchia M. other authors 1999; Prion protein of 106 residues creates an artifical transmission barrier for prion replication in transgenic mice. Cell 96:869–878 [CrossRef]
     [Google Scholar]
  41. Supattapone S., Muramoto T., Legname G., Mehlhorn I., Cohen F. E., DeArmond S. J., Prusiner S. B., Scott M. R. 2001; Identification of two prion protein regions that modify scrapie incubation time. J Virol 75:1408–1413 [CrossRef]
     [Google Scholar]
  42. Taniguchi S., Suzuki N., Masuda M., Hisanaga S., Iwatsubo T., Goedert M., Hasegawa M. 2005; Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 280:7614–7623 [CrossRef]
     [Google Scholar]
  43. Taraboulos A., Scott M., Semenov A., Avrahami D., Laszlo L., Prusiner S. B., Avraham D. 1995; Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J Cell Biol 129:121–132 [CrossRef]
     [Google Scholar]
  44. Telling G. C., Haga T., Torchia M., Tremblay P., DeArmond S. J., Prusiner S. B. 1996; Interactions between wild-type and mutant prion proteins modulate neurodegeneration in transgenic mice. Genes Dev 10:1736–1750 [CrossRef]
     [Google Scholar]
  45. Touil F., Pratt S., Mutter R., Chen B. 2006; Screening a library of potential prion therapeutics against cellular prion proteins and insights into their mode of biological activities by surface plasmon resonance. J Pharm Biomed Anal 40:822–832 [CrossRef]
     [Google Scholar]
  46. Trevitt C. R., Collinge J. 2006; A systematic review of prion therapeutics in experimental models. Brain 129:2241–2265 [CrossRef]
     [Google Scholar]
  47. Williamson R. A., Peretz D., Pinilla C., Ball H., Bastidas R. B., Rozenshteyn R., Houghten R. A., Prusiner S. B., Burton D. R. 1998; Mapping the prion protein using recombinant antibodies. J Virol 72:9413–9418
     [Google Scholar]
  48. Zahn R., Liu A., Luhrs T., Riek R., von Schroetter C., Lopez Garcia F., Billeter M., Calzolai L., Wider G., Wuthrich K. 2000; NMR solution structure of the human prion protein. Proc Natl Acad Sci U S A 97:145–150 [CrossRef]
     [Google Scholar]
  49. Zou W. Q., Zheng J., Gray D. M., Gambetti P., Chen S. G. 2004; Antibody to DNA detects scrapie but not normal prion protein. Proc Natl Acad Sci U S A 101:1380–1385 [CrossRef]
     [Google Scholar]
/content/journal/jgv/10.1099/vir.0.82601-0
Loading
Discriminating between cellular and misfolded prion protein by using affinity to 9-aminoacridine compounds
J. Gen. Virol. 88, 1392 (2007); https://doi.org/10.1099/vir.0.82601-0
/content/journal/jgv/10.1099/vir.0.82601-0
/content/journal/jgv/10.1099/vir.0.82601-0
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error